Moleculin Comments on Recent FDA Drug Approvals for Acute Myeloid Leukemia
HOUSTON, TX--(Marketwired - August 09, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are …